Resveratrol reduces inflammatory responses in peripheral blood mononuclear cells from patients with severe asthma

BACKGROUND: Severe asthma is a chronic inflammatory airway disease frequently associated with neutrophilic inflammation, corticosteroid resistance, and persistent activation of pro-inflammatory signaling pathways, including nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs). OBJECTIVE: This study aimed to investigate the effects of resveratrol on inflammatory responses in peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects and patients with severe asthma. MATERIALS AND METHODS: M). Cell viability was assessed using the MTT assay, cytokine levels (IL-6, IL-8, and IL-10) were measured by ELISA, and intracellular signaling pathways (NF-κB, ERK1/2, and p38 MAPK) were evaluated by flow cytometry. RESULTS: Resveratrol did not affect cell viability and significantly reduced IL-6 and IL-8 production in a dose-dependent manner in LPS-stimulated PBMCs, without altering IL-10 levels. Additionally, resveratrol attenuated the phosphorylation of NF-κB, ERK1/2, and p38 MAPK in both monocytes and lymphocytes from healthy individuals and patients with severe asthma. DISCUSSION AND CONCLUSION: Resveratrol exerts significant anti-inflammatory effects in human PBMCs by modulating cytokine production and key intracellular signaling pathways associated with severe asthma, suggesting its potential as a complementary therapeutic strategy.